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Background: Angiogenesis plays a role in tumor growth and is partly mediated by factors in both the fibroblast
growth factor (FGF) and vascular endothelial growth factor (VEGF) pathways. Durable clinical responses with VEGF
tyrosine kinase inhibitors (TKIs) may be limited by intrinsic tumor resistance. We hypothesized that FGF signaling
may impact clinical responses to sorafenib.
Methods: Nephrectomy material was available from 40 patients with metastatic renal cell carcinoma (RCC) enrolled
in a phase II clinical trial of sorafenib ± interferon (ClinicalTrials.gov Identifier NCT00126594). Fibroblast growth factor
receptor 1 (FGFR1) and fibroblast growth factor receptor substrate 2 alpha (FRS2α) expression was assessed by in
situ hybridization and immunofluorescence, respectively. The relationship between fibroblast growth factor pathway
marker levels and progression-free survival (PFS) was analyzed using Kaplan-Meier and Cox proportional hazards
regression methods.
Results: Univariate analysis indicated that more intense FGFR1 staining was associated with shorter PFS (log-rank
P = 0.0452), but FRS2α staining was not significantly associated with PFS (log-rank P = 0.2610). Multivariate Cox
proportional hazards regression models were constructed for FGFR1 and FRS2α individually, adjusting for baseline
Eastern Cooperative Oncology Group performance status, treatment arm and anemia status. When adjusted for
each of these variables, the highest intensity level of FGFR1 (level 3 or 4) had increased progression risk relative
to the lowest intensity level of FGFR1 (level 1) (P = 0.0115). The highest intensity level of FRS2α (level 3 or 4) had
increased progression risk relative to the lowest intensity level of FRS2α (level 1) (P = 0.0126).
Conclusions: Increased expression of FGFR1 and FRS2α was associated with decreased PFS among patients with
metastatic RCC treated with sorafenib. The results suggest that FGF pathway activation may impact intrinsic
resistance to VEGF receptor inhibition.
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Cancers of the kidney and renal pelvis affect more
than 61,000 patients annually and the most common
pathological subtype is clear cell renal cell carcinoma
(ccRCC) [1]. Over 13,000 patients die annually from
RCC, making it one of the top 10 leading causes of* Correspondence: ejonasch@mdanderson.org
†Equal contributors
2Department of Genitourinary Medical Oncology, The University of Texas MD
Anderson Cancer Center, Houston, USA
Full list of author information is available at the end of the article
© 2015 Ho et al.; licensee BioMed Central. Thi
Attribution License (http://creativecommons.o
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.cancer deaths. Contemporary treatments include inhibitors
of vascular endothelial growth factor receptor (VEGFR)
and mammalian target of rapamycin (mTOR); the choice
of inhibitors is currently empirical and resistance to treat-
ment typically occurs [2].
Angiogenesis plays a key role in the growth of many
tumors and is mediated by growth factors in both the
fibroblast growth factor (FGF) and VEGF families [3,4].
Durable clinical responses with current VEGF tyrosine
kinase inhibitors (TKIs) may be limited by acquired or
intrinsic tumor resistance. Acquired resistance to VEGFs is an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
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vation of VEGF-independent pathways with secondary
activation of proangiogenic ligands from the FGF family
[5,6]. Fibroblast growth factor-2 expression is increased in
post-VEGF TKI treatment biopsies further supporting the
role of FGF signaling in acquired resistance [7].
There are four FGF tyrosine kinase membrane receptors
(FGFRs): FGFR1, −2, −3 and −4 [8]. FGFs bind their
receptors to mediate cell proliferation, angiogenesis,
and aberrant pathway activation associated with tumor
neovascularization. Downstream targets of FGFR signaling
include fibroblast growth factor receptor substrate 2 alpha
(FRS2α), which promotes cell proliferation [9]. Intrinsic
resistance to TKIs is associated with poor clinical
outcomes and overexpression of FGFR1,-2 has been
observed in RCC [10,11]. However, the impact of expres-
sion of FGF signaling components on response to first-line
treatment TKIs is unknown. We hypothesized that FGF
signaling may impact response to sorafenib, a TKI whose
targets include VEGFR2 and platelet-derived growth factor
receptor (PDGFR) [12].
Our retrospective analysis of a phase II clinical trial
suggest that increased expression of FGFR1 and FRS2α
is associated with decreased progression-free survival
(PFS) in patients with RCC treated with first-line sorafenib.
The results suggest that FGF pathway activation may
be associated with intrinsic tumor resistance to sorafenib.
Methods
Clinical samples
In a prospective phase II trial, untreated patients with
metastatic clear cell RCC were randomly allocated to
receive sorafenib 400 mg orally twice daily with or
without subcutaneous interferon α (0.5 million units
twice daily). Eighty participants were enrolled from June
25, 2005 through June 18, 2007 [13]. Primary endpoints
included the objective response rate (ORR) and safety.
Secondary endpoints included progression-free survival
(PFS) and overall survival (OS). All patients had signed an
informed consent approved by The University of Texas MD
Anderson Cancer Center institutional review board under
protocols 2003–0982 and 2004–0526 (ClinicalTrials.gov
Identifier NCT00126594). An experienced genitourinary
pathologist (P.T.) centrally reviewed hematoxylin-eosin
slides for available patient tumors (n = 40) in order to
confirm histological classification and standardize patho-
logic features.
Statistical methods
Associations between marker levels and clinical variables
(sex, ethnicity, performance status, prognostic risk, and
anemia defined as hemoglobin level <14 g/dL for men or
<12 g/dL for women) were analyzed using the Fisher’s
exact test. PFS was analyzed with regard to marker levelsfor FGFR1 and FRS2α in a cohort of 40 patients with
available nephrectomy specimens. PFS was defined as
the number of months from the start of chemotherapy,
until a patient’s death or disease progression. Patients
whose disease had not progressed were censored at the
last follow-up date. Patients whose disease had not
progressed before starting a new treatment were censored
at the new treatment start date. The relationship
between tumor marker levels and PFS was analyzed using
Kaplan-Meier and Cox proportional hazards regression
methods. Because the phase II study used the Pocock-
Simon minimization method [14] to randomize patients
to treatment arms, the balancing variables were included
in the multivariate models along with the treatment arm
[15]. These variables included ECOG performance status
(1 vs 0) and baseline anemia (No vs Yes, where Yes is
based on Hb < 14 for males and Hb < 12 for females).
Although randomization procedures also balanced
treatment arms on nephrectomy (No vs Yes) and LDH
(Not elevated vs Elevated, where Elevated is > 1.5× ULN),
none of the 40 patients in the biomarker study had elevated
LDH and all had a nephrectomy; therefore, the multivariate
models were not adjusted for these two factors. Other
prognostic factors, such as corrected calcium, were not
available. All P-values were two tailed and considered
significant at α < 0.05. Analyses were conducted using SAS
for Windows (release 9.1, SAS Institute, Cary, NC, USA).
Tissue microarrays
Tissue microarrays were generated using an arrayer
(Beecher Instruments, Inc., Sun Prairie, WI) with 0.6-mm
cores in triplicate for each case. The slides were scanned
with the Leica Microsystem (Leica Microsystems Inc.
Buffalo Grove, IL) at 20X using the Ariol Scan Station. The
Ariol system (Applied Imaging, San Jose, CA) was used to
analyze images. Areas of viable tumor were gated by a
genitourinary pathologist (P.T.) for analysis; areas of
non-viable tumor and non-tumor tissue were excluded. A
cytoplasmic algorithm was applied using the multi-stain
version of the software. Digitally, the DAB stained cells
would be positive and the negative cells stained with
hematoxlin would be measured for area. We used
TMA Navigator software (Applied Imaging, San Jose, CA)
to quantitate the tumor (scale of 0–100) intensity and
stratification of biomarkers into quartiles for each core at
20X magnification.
Histology, In Situ Hybridization (ISH), and
Immunofluorescence (IF)
Four-micron paraffin sections are cut and dried at room
temperature for 30 minutes prior to being placed in the
oven at 56°C overnight. The in situ hybridization for FGFR1
was performed using a protocol as previously described
[16]. Immunofluorescence using primary antibodies (FRS2α)
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used as a nuclear counterstain. The Ariol imaging platform
was used to stratify the specimens based on intensity
of staining for FGF biomarkers (FGFR1 ISH, FRS2α IF);
the stratification was independently confirmed by a
pathologist (P.T.).
Results
The baseline patient characteristics are denoted in
supplemental information, Table 1 for the previously
reported phase II clinical trial of first-line sorafenib
therapy in metastatic RCC [13]. Seventy-three percent
of study participants were male. Participants had an
ECOG status of 0 (68%) or 1 (32%), and all had a
Memorial Sloan-Kettering Cancer Center (MSKCC)
prognostic risk of low or intermediate except for 1
patient categorized as poor and 1 patient with missing
data. Race/ethnicity was white, non-Hispanic for 80%
and Hispanic, Black, or Native American for 20%
(Additional file 1: Table S1). At baseline, 37% of the patients
had anemia and 63% did not. Patient age at registration
ranged from 45 to 83 years of age (mean 62.38, SD 8.59).
To examine the relationship between expression of
FGF biomarkers and PFS, a tissue microarray representing
clear cell RCC specimens from patients with available
tumor and enrolled on the trial was constructed. Expression
of FGFR1 and FRS2α were analyzed by ISH/IF and stratified
into 3 categories (low, level 1; intermediate, level 2; high,
level 3 or 4) (Figure 1). We did not observe an associationTable 1 Univariate cox proportional hazards regression mode
Variable Progressed Tot
PFS (29 of 40 progressed)
Treatment arm
Sorafenib 19 22








(level 1) 3 8
(level 2) 15 19
(level 3 or 4) 11 13
FRS2α
(level 1) 3 7
(level 2) 17 21
(level 3 or 4) 9 12
ECOG, Eastern Cooperative Oncology Group; FGFR1, fibroblast growth factor receptorwith FGFR1 intensity with patient characteristics (sex,
ethnicity, ECOG performance status, MSKCC prognostic
risk category or anemia). Only baseline anemia was associ-
ated with FRS2α intensity (P = 0.0168), Additional file 2:
Table S2 and Additional file 3: Table S3.
In univariate models, PFS was associated with ECOG
performance status (P = 0.0003), anemia (P = 0.0299) and
FGFR1 expression (P = 0.0218), Table 1. The median
PFS for the total sample was 7.56 (95% CI 4.07 to
10.25) months. Median PFS by FGFR1 intensity was
5.49 (95% CI 3.48 to 11.07) months for those with the high-
est intensities (level 3 or 4), 5.52 (95% CI 3.55 to 10.25)
months for those with intermediate intensity (level 2),
and 11.14 (95% CI 9.20, not attained) months for
those with the lowest FGFR1 intensity (level 1). Similarly,
median PFS by FRS2α intensity was 4.07 (95% CI 1.81 to
11.07) months for those with the highest intensities
(level 3 or 4), 7.56 (95% CI 3.68 to 10.25) months for
those with intermediate intensity (level 2), and 11.14
(95% CI 5.45, not attained) months for those with
lowest FRS2α intensity (level 1). Kaplan-Meier curves
indicated that more intense FGFR1 staining was associ-
ated with shorter PFS (P = 0.0452), but FRS2α staining
was not significantly associated with PFS (P = 0.2610)
(Figures 2 and 3).
ECOG performance status, baseline anemia, nephrec-
tomy and LDH were balancing variables used during
the randomization of patients to treatment arm. Multi-
variate Cox proportional hazards regression models werels of progression free survival from chemotherapy start
al HR 95% CI P
2.05 0.95, 4.45 0.0683
1.00
4.95 2.07, 11.84 0.0003
1.00
2.37 1.09, 5.17 0.0299
1.00
1.00
3.54 1.02, 12.29 0.0463
4.56 1.25, 16.66 0.0218
1.00
2.07 0.60, 7.18 0.2498
2.87 0.77, 10.66 0.1146
1; FRS2α, fibroblast growth factor receptor substrate 2 alpha; HR, hazard ratio.
Figure 1 Fibroblast growth factor receptor 1 and fibroblast growth factor receptor substrate 2 alpha expression. Intensity levels were stratified
using the Ariol imaging platform (higher number corresponds to higher intensity) in renal cell carcinoma. Non-tumor tissue was excluded from
analysis. (A) In situ hybridization for localization of FGFR1 message. (B) FRS2α immunofluorescence.
Figure 2 Progression-free survival curves (PFS) with number at risk stratified by FGFR1 intensity. The Ariol imaging platform was used to stratify
the specimens based on intensity of in situ hybridization staining for FGFR1. Non-tumor tissue was excluded from analysis. The differences across
FGFR1 intensity strata were statistically significant with better progression-free survival among those patients with the lowest FGFR1 intensity
(level 1) in univariate analysis; P = 0.0452.
Ho et al. BMC Cancer  (2015) 15:304 Page 4 of 7
Figure 3 Progression-free survival curves (PFS) with number at risk stratified by FRS2α intensity. The Ariol imaging platform was used to stratify
the specimens based on intensity of immunofluorescence staining for FRS2α. Non-tumor tissue was excluded from analysis. The differences across
FRS2α intensity strata were not statistically significant in univariate analysis; P = 0.2610.
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for baseline ECOG performance status, treatment arm
and baseline anemia (Tables 2 and 3). When adjusted for
each of these factors, the risk of progression was sig-
nificantly higher for tumors with the highest intensity
level of FGFR1 (level 3 or 4) (HR 5.92, 95% CI 1.49
to 23.56, P = 0.0115) and for those with an intermediate
intensity level of FGFR1 (level 2) (HR 4.21, 95% CI 1.13 to
15.72, P = 0.0326) relative to the risk among those
with the lowest intensity level of FGFR1 (level 1).
Tumors with the highest intensity level of FRS2α
(level 3 or 4) had increased risk of progression relative to
those with the lowest intensity level of FRS2α (level 1)
(HR 7.32, 95% CI 1.53 to 34.97, P = 0.0126); progres-
sion risk did not differ significantly between those
with intermediate versus low FRS2α intensity (level 2
vs. level 1) (HR 2.96, 95% CI 0.76 to 11.45, P = 0.1161).
Our data indicates that increased expression of FGFR1
and FRS2α is associated with a worse PFS on first-line
sorafenib treatment.Table 2 Multivariate cox proportional hazards regression mode
start by FGFR1 intensity level
Variable Level Hazard ratio 9
Treatment arm Sorafenib vs. Sorafenib + interferon 1.581
ECOG Status 1 vs. 0 4.630
Anemia Yes vs. No 1.481
FGFR1 Intensity (3 or 4) vs. 1 5.925
2 vs. 1 4.209
ECOG, Eastern Cooperative Oncology Group; FGFR1, fibroblast growth factor receptDiscussion
Patients that do not initially benefit from tyrosine kinase
inhibition may have intrinsically resistant tumors. We
investigated expression of FGF pathway components in
patients with metastatic RCC treated in a randomized
phase II clinical trial that yielded no differences in PFS
between sorafenib versus sorafenib + interferon α [13].
In our current study, expression of FGFR1 and FRS2α
was not associated with MKSCC prognostic risk categories.
Using univariate and multivariate analyses, we observed
that increased expression of FGFR1 is associated with a
shorter PFS in patients treated with first-line sorafenib. In
the phase II trial design, to balance the prognostic factors
between treatment arms, the Pocock-Simon minimization
method was used to randomize patients and balance
prognostic factors such as ECOG performance status,
baseline anemia, nephrectomy, and LDH. The highest
FRS2α expression levels were associated with a shorter
PFS after adjustment for study treatment, baseline anemia
or performance status.l to predict progression-free survival from chemotherapy







Table 3 Multivariate cox proportional hazards regression model to predict progression-free survival from chemotherapy
start by FRS2α intensity level
Variable Level Hazard ratio 95% Hazard ratio confidence limits Probability > Chi square test
Treatment arm Sorafenib vs. Sorafenib + interferon 1.915 0.850 4.314 0.1171
ECOG Status 1 vs. 0 4.651 1.508 14.341 0.0075
Anemia Yes vs. No 1.831 0.628 5.342 0.2683
FRS2α Intensity (3 or 4) vs. 1 7.318 1.531 34.971 0.0126
2 vs. 1 2.959 0.765 11.449 0.1161
ECOG, Eastern Cooperative Oncology Group; FRS2α, fibroblast growth factor receptor substrate 2 alpha.
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FGF signaling can promote cell proliferation, cell
migration and tumorigenesis [5,6]. VEGFR2 blockade
transiently stops tumor growth and is followed by
tumor progression and restoration of tumor-associated
endothelium. Blockade of the FGF pathway using
adenoviral delivery of a soluble FGFR2, which acts as
a FGF-trap, decreases secondary angiogenesis after
VEGFR2 blockade suggesting that FGF inhibition may
block acquired VEGF-independent pathways [5]. Consistent
with this hypothesis, soluble high affinity decoy FGF
receptors inhibit cell proliferation and treatment with
a FGF ligand trap blocks VEGF-independent reactivation
of tumor angiogenesis in a mouse model of pancreatic
neuroendocrine tumors [4,18].
All currently approved targeted therapies for metastatic
RCC (sunitinib, sorafenib, temsirolimus, everolimus,
bevacizumab, pazopanib and axitinib) lack FGFR
activity [19]. In a phase II study of dovitinib, a TKI that
inhibits FGFR and VEGFR, as second-line therapy in
metastatic RCC, the disease control rate ≥ 4 months was
51% [20]. However, no amplification of FGFR1,-2,-3 by
PCR was detected in archival tissue suggesting that
PCR may not accurately reflect FGF activation after
progression on first-line therapy. In a phase III trial
comparing dovitinib with sorafenib as third-line
targeted therapy in metastatic RCC, there were no
differences in efficacy outcomes suggesting that there
may be other mechanisms of VEGF-targeted therapy
than FGF activation [21].
Our study has several limitations. Although the
samples were part of a randomized clinical trial, our
sample size (N = 40) was small in comparison to prior
studies [20,21] as tissue was not available from all
enrolled patients, limiting the validity of the observations
to the cohort. We did not directly compare our ISH/IF
assay with other FGF assays such as PCR amplification of
FGFR or FGF serum levels. RCC has intratumoral
heterogeneity and we attempted to control for macroscopic
heterogeneity by using the Ariol platform to exclude
stroma and stratify the ISH/IF intensities, however it is
unknown whether FGFR1/FRS2α expression in FFPE
nephrectomy samples is concordant with expression indistant metastases [22,23]. The Ariol platform, as an
automated quantitative analysis, has been studied with
other biomarkers with concordance between manual
and automated scoring [24], however it is unknown
the limitations of our IHC/IF assay with respect to
formalin-fixed paraffin-embedded age or fixation con-
ditions. The study was retrospective and FGF activation
was not used in the initial stratification of treatment arms.
There are also likely additional mechanisms beyond FGF
activation [25] that contribute to intrinsic TKI resistance
and we did not evaluate other commonly used TKIs
such as pazopanib or sunitinib. Future investigation is
warranted to determine whether these markers are associ-
ated with response to other TKIs.
The results from our study, which used FGFR1 ISH
and FRS2α IF to assess FGF activation pre-treatment,
could be used to build predictive models in RCC to
prospectively identify patients who would benefit from
therapeutic strategies targeting both VEGF and FGF
signaling in the first-line setting. FGF pathway activation
may contribute to intrinsic VEGF TKI resistance, or
angiogenesis in tumors with FGF activation may be
less dependent on VEGF-mediated pathways. Predictive
biomarkers of intrinsic VEGF TKI resistance are lacking
and the efficacy of dual inhibition of FGF and VEGF in
the subset of patients with increased FGFR1 expression
prior to treatment requires further study.
Conclusions
Increased expression of FGFR1 or FRSα was associated
with decreased PFS in a phase II clinical trial of patients
with metastatic RCC treated with first-line sorafenib.
The results suggest that FGF pathway activation may be
associated with an intrinsic resistance to VEGF receptor
inhibition.
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Characteristics.
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